459 related articles for article (PubMed ID: 35483452)
1. Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.
Aghai-Trommeschlaeger F; Zimmermann S; Gesierich A; Kalogirou C; Goebeler ME; Jung P; Pelzer T; Kurlbaum M; Klinker H; Isberner N; Scherf-Clavel O
Clin Biochem; 2022; 105-106():35-43. PubMed ID: 35483452
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Zhao J; Yan D; Li Y; Xu X; Li F; Zhang S; Jin J; Qiu F
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Apr; 1237():124100. PubMed ID: 38547701
[TBL] [Abstract][Full Text] [Related]
4. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS.
Li Y; Meng L; Ma Y; Li Y; Xing X; Guo C; Dong Z
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889345
[TBL] [Abstract][Full Text] [Related]
5. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry.
Balakirouchenane D; Khoudour N; Guégan S; Kramkimel N; Franck N; Rodier T; Goldwasser F; Dupin N; Aractingi S; Vidal M; Blanchet B
J Pharm Biomed Anal; 2021 Jan; 193():113718. PubMed ID: 33166838
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.
Nijenhuis CM; Haverkate H; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2016 Jun; 125():270-9. PubMed ID: 27058232
[TBL] [Abstract][Full Text] [Related]
8. High-performance Liquid Chromatographic Ultraviolet Detection of Nilotinib in Human Plasma from Patients with Chronic Myelogenous Leukemia, and Comparison with Liquid Chromatography-Tandem Mass Spectrometry.
Nakahara R; Satho Y; Itoh H
J Clin Lab Anal; 2016 Nov; 30(6):1028-1030. PubMed ID: 27194024
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a new HPLC-DAD method for quantification of sofosbuvir in human serum and its comparison with LC-MS/MS technique: Application to a bioequivalence study.
Miraghaei S; Mohammadi B; Babaei A; Keshavarz S; Bahrami G
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1063():118-122. PubMed ID: 28858753
[TBL] [Abstract][Full Text] [Related]
10. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.
Krens SD; van der Meulen E; Jansman FGA; Burger DM; van Erp NP
Biomed Chromatogr; 2020 Mar; 34(3):e4758. PubMed ID: 31758580
[TBL] [Abstract][Full Text] [Related]
11. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
13. Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio.
Zimmermann S; Aghai F; Schilling B; Kraus S; Grigoleit GU; Kalogirou C; Goebeler ME; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
J Pharm Biomed Anal; 2022 Mar; 211():114623. PubMed ID: 35121279
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of High-Throughput Bioanalytical Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the Quantification of Newly Synthesized Antitumor Carbonic Anhydrase Inhibitors in Human Plasma.
Abdel-Megied AM; Eldehna WM; Abdelrahman MA; Elbarbry FA
Molecules; 2020 Dec; 25(23):. PubMed ID: 33291270
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
Zhou L; Wang S; Chen M; Huang S; Zhang M; Bao W; Bao A; Zhang P; Guo H; Liu Z; Xie G; Gao J; Wu Z; Lou Y; Fan G
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122752. PubMed ID: 33991955
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
Huynh HH; Pressiat C; Sauvageon H; Madelaine I; Maslanka P; Lebbé C; Thieblemont C; Goldwirt L; Mourah S
Ther Drug Monit; 2017 Feb; 39(1):43-54. PubMed ID: 27861317
[TBL] [Abstract][Full Text] [Related]
17. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib.
Veerman GDM; Lam MH; Mathijssen RHJ; Koolen SLW; de Bruijn P
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Apr; 1113():37-44. PubMed ID: 30889498
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
Ishikawa E; Yokoyama Y; Chishima H; Kuniyoshi O; Sato I; Nakaya N; Nakajima H; Kimura M; Hakamata J; Suehiro N; Nakada H; Ikemura S; Jibiki A; Kawazoe H; Muramatsu H; Suzuki S; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1199():123245. PubMed ID: 35436724
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Drug Monitoring in Oncohematological Patients: A Fast and Accurate HPLC-UV Method for the Quantification of Nilotinib in Human Plasma and Its Clinical Application.
Escudero-Ortiz V; Rodríguez-Lucena FJ; Estan-Cerezo G; Mancheño-Maciá E; Conesa-García V; García-Monsalve A; Soriano-Irigaray L; Navarro-Ruiz A
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]